Evaluation of miR‐371a‐3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection-Reference-Cited by-同舟云学术

Evaluation of miR‐371a‐3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection

Published:2022-11-02 Issue:4 Volume:11 Page:634-640
ISSN:2047-2919
Container-title:Andrology
language:en
Short-container-title:Andrology

Author:

Konneh Bendu¹²^ORCID,Lafin John T.¹^ORCID,Howard Jeffrey¹,Gerald Thomas¹,Amini Armon¹,Savelyeva Anna¹,Woldu Solomon L.¹,Lewis Cheryl M.³,Jia Liwei³,Margulis Vitaly¹⁴,Coleman Nicholas⁵⁶,Scarpini Cinzia⁵,Frazier A. Lindsay⁷,Murray Matthew J.⁵⁸^ORCID,Amatruda James F.⁹,Bagrodia Aditya¹¹⁰

Affiliation:

1. Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA

2. Department of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA

3. Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA

4. Department of Urology I.M. Sechenov First Moscow State University Moscow Russia

5. Department of Pathology University of Cambridge Cambridge UK

6. Department of Histopathology Cambridge University Hospitals NHS Foundation Trust Cambridge UK

7. Department of Pediatric Hematology and Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

8. Department of Paediatric Hematology and Oncology Cambridge University Hospitals NHS Foundation Trust Cambridge UK

9. Cancer and Blood Disease Institute Children's Hospital Los Angeles Los Angeles California USA

10. Department of Urology University of California San Diego San Diego California USA

Funder

Cancer Prevention and Research Institute of Texas

Publisher

Wiley

Subject

Urology,Endocrinology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/andr.13317

Reference15 articles.

1. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007

2. Long-term Morbidity of Testicular Cancer Treatment

3. Serum tumor markers in the evaluation of male germ cell tumors

4. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours

5. Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNA for Prediction of Teratoma and Viable Germ Cell Tumor after Chemotherapy;Urologic Clinics of North America;2024-08

2. Retroperitoneal Lymph Node Dissection in Patients with Stage II Seminomatous Germ Cell Tumour;European Urology Focus;2024-05

3. Reply to Fumihiko Urabe, Takashi Yoshioka, and Takahiro Kimura’s Letter to the Editor re: Felix Seelemeyer, David Pfister, Robert Pappesch, Sabine Merkelbach-Bruse, Pia Paffenholz and Axel Heidenreich. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021;European Urology Oncology;2024-04

4. Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum;Journal of Urology;2024-01

5. A systematic review of pN0 testicular seminoma: a new clinical entity and future directions;Urologic Oncology: Seminars and Original Investigations;2023-12